ARID1A and neoplasm: Li et al. found that ARID1A mutations were associated with increased immune activity in gastrointestinal cancer by causing MSI, and increased tumor mutational burden (TMB), producing more tumor-associated antigens and, thus, promoting anti-tumor immunity [153].